Eli Lilly (LLY) is experiencing remarkable growth, with sales of its GLP-1 drugs, Mounjaro and Zepbound, skyrocketing by 99% and 175%, respectively, in 2025. This surge has contributed to a staggering 1,100% increase in Eli Lilly’s stock over the past decade, significantly outpacing the S&P 500’s 230% gain. However, despite this impressive performance, the stock’s current price-to-earnings (P/E) ratio stands at 39x, well above the industry average of 23x, raising concerns about its valuation.
The competitive landscape poses additional risks for Eli Lilly. As patents on Mounjaro and Zepbound approach expiration, the potential for generic competition looms large, threatening future revenue streams. Moreover, rivals such as Novo Nordisk and Pfizer are also advancing in the GLP-1 market, intensifying the challenge for Eli Lilly to maintain its leading position.
For investors, the key takeaway is clear: while Eli Lilly has demonstrated exceptional growth, its high valuation and the inherent risks in the pharmaceutical sector warrant careful consideration before making investment decisions.
Source: fool.com